Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01525550 · ClinicalTrials.gov registry record · Phase 4
A Study Of The Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors
A Phase 4 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 4
- Development phase
- 106
- Enrollment target
NCT01525550 is a Phase 4 study that has completed, run by Pfizer. The registered enrollment target is 106 participants.
The verdict
NCT01525550, a Phase 4 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 106 participants
- Enrollment target
Study Summary
The purpose of this study is to confirm the safety and efficacy of sunitinib in subjects with unresectable pancreatic neuroendocrine tumors.
Interventions
- DRUG sunitinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 106 participants |
| Start Date | 2012-06-06 |
| Est. Completion | 2018-07-26 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01525550
The ClinicalTrials.gov registry entry for NCT01525550 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 106 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which sunitinib is the first listed.
NCT01525550 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01525550 about?
NCT01525550 is a clinical study titled "A Study Of The Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors". The purpose of this study is to confirm the safety and efficacy of sunitinib in subjects with unresectable pancreatic neuroendocrine tumors.
What is the current status of trial NCT01525550?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 106 participants. The study started on 2012-06-06. Estimated completion is 2018-07-26.
What interventions are being tested in trial NCT01525550?
The interventions under investigation include: sunitinib (DRUG).
Who is sponsoring clinical trial NCT01525550?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.